Depemokimab is an ultra-long-acting biologic therapy designed to treat severe asthma with an eosinophilic phenotype.
It functions by binding to interleukin-5 (IL-5) with enhanced affinity, which allows for effective dosing intervals of every six months.
This mechanism targets and reduces eosinophil levels, which are implicated in the pathophysiology of eosinophilic asthma.
Depemokimab was administered subcutaneously at a dose of 100 mg at weeks 0 and 26, in addition to standard care.
The study included patients with severe asthma characterized by high eosinophil counts and a history of exacerbations despite medium- or high-dose inhaled glucocorticoids.
Depemokimab reduced the annualized rate of exacerbation among patients with severe asthma with an eosinophilic phenotype (SWIFT investigators).